Chiara Conti, Anna D’Annunzio, Pierfrancesco Reverberi
{"title":"数据驱动的健康创新和隐私监管","authors":"Chiara Conti, Anna D’Annunzio, Pierfrancesco Reverberi","doi":"10.1515/bejeap-2023-0020","DOIUrl":null,"url":null,"abstract":"Abstract Data-driven health innovation may lead to develop targeted treatments using health data. We consider privacy-sensitive patients who may decide to share personal health data if compensated. Each patient does not internalize the impact of sharing data on drug innovation. We show that investment incentives in targeted treatments are too weak as long as such innovation has a public good nature so that patients can free ride on sharing health data. Then, privacy protection measures reducing data sharing risks can promote pharmaceutical R&D and social welfare.","PeriodicalId":47400,"journal":{"name":"B E Journal of Economic Analysis & Policy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Data-Driven Health Innovation and Privacy Regulation\",\"authors\":\"Chiara Conti, Anna D’Annunzio, Pierfrancesco Reverberi\",\"doi\":\"10.1515/bejeap-2023-0020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Data-driven health innovation may lead to develop targeted treatments using health data. We consider privacy-sensitive patients who may decide to share personal health data if compensated. Each patient does not internalize the impact of sharing data on drug innovation. We show that investment incentives in targeted treatments are too weak as long as such innovation has a public good nature so that patients can free ride on sharing health data. Then, privacy protection measures reducing data sharing risks can promote pharmaceutical R&D and social welfare.\",\"PeriodicalId\":47400,\"journal\":{\"name\":\"B E Journal of Economic Analysis & Policy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B E Journal of Economic Analysis & Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/bejeap-2023-0020\",\"RegionNum\":4,\"RegionCategory\":\"经济学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ECONOMICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B E Journal of Economic Analysis & Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/bejeap-2023-0020","RegionNum":4,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ECONOMICS","Score":null,"Total":0}
Data-Driven Health Innovation and Privacy Regulation
Abstract Data-driven health innovation may lead to develop targeted treatments using health data. We consider privacy-sensitive patients who may decide to share personal health data if compensated. Each patient does not internalize the impact of sharing data on drug innovation. We show that investment incentives in targeted treatments are too weak as long as such innovation has a public good nature so that patients can free ride on sharing health data. Then, privacy protection measures reducing data sharing risks can promote pharmaceutical R&D and social welfare.
期刊介绍:
The B.E. Journal of Economic Analysis & Policy welcomes submissions that employ microeconomics to analyze issues in business, consumer behavior, and public policy. We aim to be an international forum for scholarship, whether the scholarship considers an issue that is general or that pertains to a particular country or region, but authors should bear in mind that our readers come from around the world. Potential issues of interest include: the interaction of firms, the functioning of markets, the effects of domestic and international policy, and the design of organizations and institutions.